Praveen Sharma1, Ashish Kumar2. 1. Department of Gastroenterology, Sir Ganga Ram Hospital, New Delhi, India. Electronic address: drpraveen_sharma@yahoo.com. 2. Department of Gastroenterology, Sir Ganga Ram Hospital, New Delhi, India.
Abstract
BACKGROUND AND AIMS: Liver involvement is common in COVID-19. Elevated aspartate and alanine amino transaminase (AST/ALT) and borderline increase in serum bilirubin and serum alkaline phosphatase (ALP) are the commonest findings. Patients with associated co morbid conditions like obesity, cardiovascular disease, renal disease, malignancy, hypertension and old age are prone to develop severe disease. Limited data is available in patients with COVID-19 and metabolic dysfunction associated fatty liver disease (MAFLD).The aim of this review is to analyse the effect of MAFLD on severity of COVID-19. METHODS: We systematically searched the PubMed database till May 20, 2020 and retrieved all the articles published on COVID-19 and fatty liver/MAFLD/NAFLD. RESULTS: Limited studies done had shown four to six fold high risk of severe COVID-19 in patients with MAFLD. Patients with MAFLD and associated obesity, severe fibrosis and age <60 yrs are more prone to develop severe COVID-19. CONCLUSION: MAFLD is associated with 4-6 fold increase in severity of COVID-19 compared to non MAFLD patients. Physician and hepatologist should follow these patients cautiously and preventive measures to be taken strictly in these high risk patients.
BACKGROUND AND AIMS: Liver involvement is common in COVID-19. Elevated aspartate and alanine amino transaminase (AST/ALT) and borderline increase in serum bilirubin and serum alkaline phosphatase (ALP) are the commonest findings. Patients with associated co morbid conditions like obesity, cardiovascular disease, renal disease, malignancy, hypertension and old age are prone to develop severe disease. Limited data is available in patients with COVID-19 and metabolic dysfunction associated fatty liver disease (MAFLD).The aim of this review is to analyse the effect of MAFLD on severity of COVID-19. METHODS: We systematically searched the PubMed database till May 20, 2020 and retrieved all the articles published on COVID-19 and fatty liver/MAFLD/NAFLD. RESULTS: Limited studies done had shown four to six fold high risk of severe COVID-19 in patients with MAFLD. Patients with MAFLD and associated obesity, severe fibrosis and age <60 yrs are more prone to develop severe COVID-19. CONCLUSION: MAFLD is associated with 4-6 fold increase in severity of COVID-19 compared to non MAFLD patients. Physician and hepatologist should follow these patients cautiously and preventive measures to be taken strictly in these high risk patients.
Authors: Waseem N Ahmed; Chankramath S Arun; Thanuvelil G Koshy; Abilash Nair; Prasanth Sankar; Sabeer A Rasheed; Reeja Ann Journal: J Family Med Prim Care Date: 2020-08-04
Authors: Ovidiu P Calapod; Andreea M Marin; Minodora Onisai; Laura C Tribus; Corina S Pop; Carmen Fierbinteanu-Braticevici Journal: Medicina (Kaunas) Date: 2021-04-30 Impact factor: 2.430
Authors: Patricia Lamadrid; Marta Alonso-Peña; David San Segundo; Mayte Arias-Loste; Javier Crespo; Marcos Lopez-Hoyos Journal: Front Immunol Date: 2021-03-30 Impact factor: 7.561
Authors: Jhean Gabriel Gonzáles Yovera; Marcio Jose Concepción-Zavaleta; Julia Coronado Arroyo; Diego Moreno Marreros Journal: Endocrinol Diabetes Metab Date: 2020-10-21